Results 11 to 20 of about 5,275 (178)
Principles of urate-lowering therapy: eight steps to success
Современная ревматология, 2023 Treatment of such a serious systemic disease as gout is often carried out incorrectly, despite the presence of a large number of recommendations and drugs.
O. V. Zhelyabina +2 more
doaj +2 more sources
Urate lowering therapy in primary care: rheum for improvement [PDF]
Exploration of Musculoskeletal DiseasesPrimary care physicians (PCPs) play a critical role in the management of gout worldwide. However, significant gaps in gout care persist, underscoring the need for improved approaches to its management.
Emilie Schurenberg +2 more
doaj +2 more sources
Urate-lowering therapy for patients with gout on hemodialysis. [PDF]
Int J Rheum Dis, 2022 AbstractObjectiveGout is the most common form of inflammatory arthritis and is caused by deposition of monosodium urate crystals resulting from a high burden of uric acid (UA). High UA burden also has been associated with increased morbidity and mortality in the general population and progression to chronic kidney disease.
Alkilany R, Einstadter D, Antonelli M.
europepmc +3 more sources
Perceptions About Asymptomatic Hyperuricemia and Views About Urate-Lowering Therapy in People With Asymptomatic Hyperuricemia. [PDF]
Arthritis Care Res (Hoboken)Objective Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia. Methods Participants in a multinational study of
Dalbeth N +19 more
europepmc +2 more sources
Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway
Nutrition & Metabolism, 2021 Objectives The study of sex differences in hyperuricemia can provide not only a theoretical basis for this clinical phenomenon but also new therapeutic targets for urate-lowering therapy.
Lei Liu +5 more
doaj +1 more source
Cardiac and renal protective effects of urate-lowering therapy [PDF]
Rheumatology, 2017 Patients with gout often have co-morbidities such as cardiovascular disease, renal failure and metabolic syndrome components. Some studies, but not all, have suggested that hyperuricaemia and gout are associated with increased risk of myocardial infarction, renal failure and death primarily because of increased risk of cardiovascular events. Therefore,
Pascal, Richette +2 more
openaire +2 more sources
Contentious Issues in Gout Management: The Story so Far
Open Access Rheumatology: Research and Reviews, 2021 Mohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019 ...
Talaat M, Park K, Schlesinger N
doaj
Bariatric surgery as urate-lowering therapy in severe obesity [PDF]
Annals of the Rheumatic Diseases, 2014 Gout represents a metabolically driven inflammatory arthropathy, which could be substantially influenced by adiposity and lifestyle risk factors. As such, influenced by the trends in lifestyle factors associated with Westernisation,1 ,2 gout prevalence has increased in the last few decades worldwide (eg, 3.9% of US adults (8.3 million) in 2007–20083).4
Hyon K, Choi, Yuqing, Zhang
openaire +2 more sources
Experience with canakinumab in a patient with gout and IgA nephropathy
Современная ревматология, 2019 The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine ...
E. V. Ilyinykh, M. S. Eliseev
doaj +1 more source
Kidney & Blood Pressure Research, 2018 Current urate-lowering therapy (ULT) includes three direct acting drugs (allopurinol, febuxostat, Rasburicase) and at least four ‘indirect’ drugs with other important targets (canagliflozin, losartan, fenofibrate and sevelamer).
Davide Viggiano +5 more
doaj +1 more source